Pan-cancer tRNA-derived fragment CAT1 coordinates RBPMS to stabilize NOTCH2 mRNA to promote tumorigenesis
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Transfer RNA-derived fragments (tRFs) are a class of small non-coding regulatory RNAs that are involved in the pathophysiology of many diseases. However, the role of tRFs in cancer progression remains largely elusive. Here, we demonstrate that a pan-cancer 3'-tRF, CAT1 (cancer associated tRF 1), is ubiquitously upregulated in tumors and associated with poor prognosis of a variety of cancers, including lung cancer. The upregulated CAT1 in cancer cells binds to RNA-binding protein with multiple splicing (RBPMS) and displaces NOTCH2 association from RBPMS, thereby inhibiting the subsequent CCR4-NOT deadenylation-complex-mediated NOTCH2 mRNA decay. The CAT1-enhanced NOTCH2 expression promotes lung cancer cell proliferation and metastasis in vitro and in vivo. In addition, plasma CAT1 levels are substantially increased in patients with lung cancer compared to non-cancer control subjects. Our findings reveal an intrinsic connection between cancer-specific upregulation of CAT1 and cancer progression, show the regulation of NOTCH signaling in cancer by a 3'-tRF, and highlight its great clinical potential.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Cell reports - 42(2023), 11 vom: 28. Nov., Seite 113408 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yu, Mengqian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 26.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2023.113408 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36435383X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36435383X | ||
| 003 | DE-627 | ||
| 005 | 20240127231849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2023.113408 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1272.xml |
| 035 | |a (DE-627)NLM36435383X | ||
| 035 | |a (NLM)37943661 | ||
| 035 | |a (PII)S2211-1247(23)01420-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yu, Mengqian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan-cancer tRNA-derived fragment CAT1 coordinates RBPMS to stabilize NOTCH2 mRNA to promote tumorigenesis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Transfer RNA-derived fragments (tRFs) are a class of small non-coding regulatory RNAs that are involved in the pathophysiology of many diseases. However, the role of tRFs in cancer progression remains largely elusive. Here, we demonstrate that a pan-cancer 3'-tRF, CAT1 (cancer associated tRF 1), is ubiquitously upregulated in tumors and associated with poor prognosis of a variety of cancers, including lung cancer. The upregulated CAT1 in cancer cells binds to RNA-binding protein with multiple splicing (RBPMS) and displaces NOTCH2 association from RBPMS, thereby inhibiting the subsequent CCR4-NOT deadenylation-complex-mediated NOTCH2 mRNA decay. The CAT1-enhanced NOTCH2 expression promotes lung cancer cell proliferation and metastasis in vitro and in vivo. In addition, plasma CAT1 levels are substantially increased in patients with lung cancer compared to non-cancer control subjects. Our findings reveal an intrinsic connection between cancer-specific upregulation of CAT1 and cancer progression, show the regulation of NOTCH signaling in cancer by a 3'-tRF, and highlight its great clinical potential | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CAT1 | |
| 650 | 4 | |a CP: Cancer | |
| 650 | 4 | |a CP: Molecular biology | |
| 650 | 4 | |a NOTCH2 | |
| 650 | 4 | |a RBPMS | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a gene regulation | |
| 650 | 4 | |a mRNA stability | |
| 650 | 4 | |a pan-cancer analysis | |
| 650 | 4 | |a small noncoding RNA | |
| 650 | 4 | |a tRNA-derived fragment | |
| 650 | 4 | |a tumorigenesis | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a RNA, Transfer |2 NLM | |
| 650 | 7 | |a 9014-25-9 |2 NLM | |
| 650 | 7 | |a RNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a RBPMS protein, human |2 NLM | |
| 650 | 7 | |a NOTCH2 protein, human |2 NLM | |
| 650 | 7 | |a Receptor, Notch2 |2 NLM | |
| 700 | 1 | |a Yi, Jiani |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Qiongzi |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Dongxia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Juze |e verfasserin |4 aut | |
| 700 | 1 | |a Mi, Chunyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Liyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Bingjian |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Weiguo |e verfasserin |4 aut | |
| 700 | 1 | |a Ying, Kejing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wantao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Enguo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Honghe |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Zhimin |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Pengyuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 42(2023), 11 vom: 28. Nov., Seite 113408 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:11 |g day:28 |g month:11 |g pages:113408 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2023.113408 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 11 |b 28 |c 11 |h 113408 | ||